Could Moesin Be a New Marker for Indicating Progression in Endometrial Cancer?

Area of Science:

• Oncology
• Pathology
• Biomarkers

Background:

• Endometrial cancer develops from pre-invasive lesions.
• Identifying biomarkers for progression is crucial for early detection and management.

Purpose of the Study:

• To determine the role of Ezrin, Radixin, and Moesin protein expression in endometrial cancer progression.
• To evaluate these proteins as potential biomarkers for endometrial lesions.

Main Methods:

• Immunohistochemical analysis of Ezrin, Radixin, and Moesin expression in normal endometrium, endometrial hyperplasia (with and without atypia), and endometrial cancer tissues.
• Correlation of protein expression levels with clinicopathological features and patient outcomes.

Main Results:

• Ezrin and Moesin expression were significantly higher in atypical hyperplasia compared to hyperplasia without atypia.
• Moesin expression was significantly elevated in endometrial cancer versus atypical hyperplasia.
• Increased Moesin expression correlated with higher malignancy risk and postoperative mortality.

Conclusions:

• Moesin expression serves as a potential indicator of malignancy in pre-invasive endometrial lesions.
• Elevated Moesin levels in endometrial cancer may predict disease progression and warrant close monitoring.